USFDA accepts regulatory submission for tanezumab for management of chronic pain due to osteoarthritis Medical Dialogues Bureau7 March 2020 10:00 AM ISTTanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF)...
Lower dose of Pfizer, Eli Lilly blockbuster painkiller tanezumab misses target in late stage study Farhat Nasim20 April 2019 10:00 AM ISTThe drug, tanezumab, belongs to a new category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells,...
Pfizer quarterly profit in line, touts pipeline of future products Medical Dialogues Bureau31 Jan 2019 9:05 AM ISTOn a call with analysts, new Chief Executive Albert Bourla said Pfizer had "the best pipeline in our history," and predicted that the company would...
